Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

(2016) Keith C. Ferdinand et al.   Cardiovascular Diabetology

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide

(2016) Z. Milicevic et al.   DIABETES OBESITY & METABOLISM

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

(2015) Francesco Giorgino et al.   DIABETES CARE

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

(2015) R. S. Weinstock et al.   DIABETES OBESITY & METABOLISM

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

(2015) Lawrence Blonde et al.   LANCET

Albiglutide

(2014) Jennifer M. Trujillo et al.   ANNALS OF PHARMACOTHERAPY

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Introduction

(2014)   DIABETES CARE

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

(2014) Guillermo Umpierrez et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

(2014) Carol Wysham et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

(2014) Michael Nauck et al.   DIABETES CARE

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)

(2014) Z. Skrivanek et al.   DIABETES OBESITY & METABOLISM

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

(2014) Yasuo Terauchi et al.   ENDOCRINE JOURNAL

Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

(2014) Keith C. Ferdinand et al.   HYPERTENSION

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes

(2014) Louis Kuritzky et al.   POSTGRADUATE MEDICINE

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes

(2014) Philip Raskin et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes

(2014) Gian Paolo Fadini et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2013) Stanley S. Schwartz   CURRENT MEDICAL RESEARCH AND OPINION

Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives

(2013) B. Ahrén   DIABETES & METABOLISM

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

(2013) R. A. DeFronzo et al.   DIABETES CARE

American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary

(2013) Alan Garber et al.   Endocrine Practice

Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS

(2013) L van Bloemendaal et al.   JOURNAL OF ENDOCRINOLOGY

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

(2012) J. H. DeVries et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

(2012) G. Grunberger et al.   DIABETIC MEDICINE

Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting

(2012) Howard Lando et al.   Endocrine Practice

Drug-induced hypoglycaemia in type 2 diabetes

(2012) Berit Inkster et al.   Expert Opinion On Drug Safety

Liraglutide-Induced Acute Kidney Injury

(2012) Yaman Kaakeh et al.   PHARMACOTHERAPY

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

(2011) J. J. Holst et al.   DIABETES CARE

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects

(2011) P. Barrington et al.   DIABETES OBESITY & METABOLISM

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study

(2011) G. E. Umpierrez et al.   DIABETES OBESITY & METABOLISM

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes

(2011) P. Barrington et al.   DIABETES OBESITY & METABOLISM

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

(2011) Thomas Blevins et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

(2010) Alfonso López-Ruiz et al.   PHARMACY WORLD & SCIENCE

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Exenatide-Associated Ischemic Renal Failure

(2009) W. J. Weise et al.   DIABETES CARE

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET